Revision on SomnoMed
Scott Power
Morgans
SomnoMed recently downgraded their FY15 sales guidance on the back of a poor 3Q sales result, but flag 4Q as a record setting quarter due to the growth of direct sales in the US and strong emerging markets in Europe. SOM has completed testing on the digital record transmission and will be phasing this in across their 14 services hubs over the next 7 months, saving on freight costs, higher levels of precision, and a shortened turnaround time. Following the sales guidance downgrade, we maintain an Add recommendation but revise our price target to A$2.82 (from A$3.26). Research attached access the blog site here: (VIEW LINK)
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media.
I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these sectors, which help with identification of key trends and developments.
1 stock mentioned
Scott Power
Senior Analyst
Morgans
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise
Scott Power
Senior Analyst
Morgans
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise
Comments
Comments
Sign In or Join Free to comment
most popular
Equities
How to choose excellent fund managers
Livewire Markets
Macro
The RBA should warn that it could raise rates again
Coolabah Capital